Search hospitals > Ohio > Newark
Newark Radiation Oncology
Claim this profileNewark, Ohio 43055
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
Conducts research for Non-Small Cell Lung Cancer
165 reported clinical trials
2 medical researchers
Summary
Newark Radiation Oncology is a medical facility located in Newark, Ohio. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Ovarian Cancer, Non-Small Cell Lung Cancer and other specialties. Newark Radiation Oncology is involved with conducting 165 clinical trials across 321 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and John P. Kuebler.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
126 reported clinical trials
208 drugs studied
John P. KueblerStrecker Cancer Center-Belpre13 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
1 reported clinical trial
5 drugs studied
Clinical Trials running at Newark Radiation Oncology
Lung Cancer
Bladder Cancer
Melanoma
Cutaneous Melanoma
Bladder Carcinoma
Esophageal cancer
Multiple Myeloma
Cancer
Prostate Cancer
Pancreatic Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Newark Radiation Oncology?
Newark Radiation Oncology is a medical facility located in Newark, Ohio. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Ovarian Cancer, Non-Small Cell Lung Cancer and other specialties. Newark Radiation Oncology is involved with conducting 165 clinical trials across 321 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and John P. Kuebler.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.